How can clinicians safely manage the potential cardiac risks associated with low-dose amphetamines in older adults, while ensuring the treatment's benefits outweigh the risks in cases of failure-to-thrive depression?  

There is at least a forty-year history of using low-dose amphetamines as psycho-stimulants to improve energy, appetite, mood, and initiative in older adults with failure-to-thrive depression, which is a serious and common condition pre-disposing to excessive morbidity and mortality.